PharmaBiome, a pre-clinical stage spinoff from the ETH Zurich, has developed unique technologies to access the entire range of intestinal bacteria for the design and production of function-based consortia at scale.

We met Christophe Lacroix, Founder of Pharmabiome, during the fourth edition of Microbiome Movement Drug Development Europe held in London.